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Abstract
Background: Algorithms for bone mineral density (BMD) management in HIV-infected patients are lacking. Our objective
was to assess how often a dual-energy x-ray absorptiometry (DXA) scan should be performed by assessing time of
progression to osteopenia/osteoporosis.
Methods: All DXA scans performed between 2000 and 2009 from HIV-infected patients with at least two DXA were
included. Time to an event (osteopenia and osteoporosis) was assessed using the Kaplan–Meier method. Strata (tertiles)
were defined using baseline minimum T scores. Differences between strata in time to an event were compared with the log-
rank test.
Results: Of 391 patients (1,639 DXAs), 49.6% had osteopenia and 21.7% osteoporosis at their first DXA scan. Of the 112
(28.6%) with normal BMD, 35.7% progressed to osteopenia; median progression time was 6.7 years. These patients were
stratified: ‘‘low-risk’’ (baseline minimum T score .20.2 SD), ‘‘middle-risk’’ (between 20.2 and 20.6 SD), and ‘‘high-risk’’
(from 20.6 to 21 SD); median progression time to osteopenia was 8.7, .7.2, and 1.7 years, respectively (p,0.0001). Of
patients with osteopenia, 23.7% progressed to osteoporosis; median progression time was.8.5 years. Progression time was
.8.2 years in ‘‘low-risk’’ tertile (T score between21.1 and21.6 SD),.8.5 years in ‘‘middle-risk’’ (between21.6 and22), and
3.2 years in ‘‘high-risk’’ (from 22 to 22.4) (p,0.0001).
Conclusions: Our results may help to define the BMD testing interval. The lowest T score tertiles would suggest
recommending a subsequent DXA in 1–2 years; in the highest tertiles, $6 years. Early intervention in patients with bone
demineralization could reduce fracture–related morbidity/mortality.
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Introduction
Bone strength is the result of bone mineral density (BMD) and
bone microarchitecture. A decrease in BMD leads to deterioration
of microarchitecture, and is determined by the intensity of bone
remodeling. These changes lead to critical damage and porosity
that weaken bone and increase the probability of fractures.[1]
Many factors lead to accelerated bone loss, and HIV infection is
one of the most recently identified [2,3,4]. The results of several
studies confirm a higher incidence of osteopenia and osteoporosis
in HIV-infected patients than in HIV-negative individuals. In fact,
up to 25% of infected patients fulfill the criteria for osteoporosis
and up to 50% fulfill those of osteopenia [2,3,4,5]. Accelerated
bone demineralization in this population is due to an additional
number of factors such as the HIV infection itself and the chronic
inflammatory status, by increasing apoptosis of osteoblast cells and
promotion of osteoclastic activity [6,7,8,9,10,11,12,13,14,15], the
exposure to specific antiretroviral agents [2,13,16,17,18] and the
immune reconstitution [14,19,20], together with traditional risk
factors, such as vitamin D insufficiency, a secondary cause of
osteoporosis that is very prevalent among HIV-infected patients.
[21]
In addition, the first available longitudinal studies revealed that
HIV-infected patients experience more rapid bone loss [5,19,20]
and more frequent fractures than HIV-negative individuals.
[20,22,23,24]
The high associated morbidity and mortality of bone fractures
[25] means that optimal monitoring of bone mineralization should
be offered to patients at high risk of low BMD, such as the HIV-
infected population.
Dual-energy X-ray absorptiometry (DXA) is the method of
choice for the assessment of BMD. Most clinicians attending HIV-
infected patients agree that this group should undergo DXA
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screening, especially those patients with traditional risk factors for
bone loss. [26,27] However, the optimal BMD testing intervals
remains undetermined.
This study aims to determine how often a DXA scan should be
performed in chronically HIV-infected patients by assessing the
time of progression to osteopenia or osteoporosis in a large cohort.
Methods
Study design, population, and objective
We performed a retrospective longitudinal observational study
of all DXA scans from HIV-infected patients who attended our
HIV Unit between January 2000 and December 2009.
Of a total of 671 patients with at least one DXA scan, 391 had
at least two DXA scans performed during the study period. These
scans were included in the present analysis. The study was
performed according to the stipulations of the Declaration of
Helsinki, and all patients gave their written informed consent for
their medical information to be used for purposes of scientific
research in accordance with the ethical committee of the
participating site. A more detailed description of the methodology
applied has been described elsewhere. [2]
The objective of the study was to determine the time of
progression to bone loss defined as time from normal BMD to
osteopenia and from osteopenia to osteoporosis.
Osteopenia and osteoporosis were defined following the World
Health Organization (WHO) criteria, as follows: normal, when the
T score by DXA was higher than 21.0 SD, osteopenia when the
T score was between 21.0 SD and 22.5 SD, and osteoporosis
when the T score was less than 22.5 SD. [28]
Assessments
A total of 1,639 DXA scans from 391 patients were included in
the present analysis.
The mean BMD and T score (comparison with normal
reference values for young adults expressed as standard deviation
units) for the lumbar spine and femoral neck were measured using
the same DXA device (Lunar Prodigy, GE Healthcare, Belgium)
at an external center (CETIR Grup Me`dic, Barcelona, Spain).
Epidemiological and HIV-related data (time since diagnosis of
HIV infection, time on antiretroviral treatment, viral load, CD4
T-cell count, nadir CD4 T-cell count, total time on treatment,
total time on protease inhibitors, total time on tenofovir, baseline
antiretroviral treatment, time with viral suppression, and hepatitis
B or C coinfection) were collected from the database of our HIV
Unit at time of the first DXA scan.
Statistical analysis
A descriptive analysis of the main quantitative and categorical
variables was performed.
We calculated time of progression in weeks from normal BMD
to osteopenia. The calculation was based on those individuals
whose BMD was considered normal according to a first DXA scan
and who fulfilled the criteria for osteopenia in a subsequent scan.
The same procedure was followed to compute time from
osteopenia to osteoporosis (ie, patients with osteopenia in a first
DXA scan who progressed to osteoporosis).
Patients with normal BMD at baseline and at least 3 DXA scans
who progressed from normal BMD status to osteopenia and later
to osteoporosis were considered for both time from normal BMD
status to osteopenia and time from osteopenia to osteoporosis.
The time to an event, namely, change of category (normal to
osteopenia, osteopenia to osteoporosis), was known only for those
patients who presented the event before the last DXA scan. For
the remaining patients, the only known data were that the time to
the event was greater than the observation time. This approach is
known as administrative censoring, and the incomplete data are
termed right-censored. [29]
Additionally, data were stratified by tertiles of the baseline T
score. These distinct groups represent the BMD baseline status.
The initial value is related to the time to an event, assuming that
the T score is a monotone and decreases over time.
Survival was analyzed using the Kaplan-Meier estimator; the
log-rank test was used to compare strata. If the last time of
observation is not censored, then the curve fall to zero and an
exact value of time is provided while, if the last observed time is
censored, the survival remains constant from the last time value
and result is provided as ‘‘.than’’ this value.
All analyses were performed using the R software, and all
reported p values are two-tailed.
Results
Epidemiological and clinical data are summarized in Table 1.
At the first DXA scan, 112 patients of 391 (28.6%) had normal
BMD, 194 (49.6%) fulfilled the criteria for osteopenia, and 85
(21.7%) fulfilled the criteria for osteoporosis.
The mean (SD) number of DXA scans per patient (DXA scans/
patient) was 4 (2); 100% of patients had 2 DXA scans, 67% had 3
DXA scans, 48% had 4 DXA scans, and 35% had 5 or more. No
differences were observed in mean (SD) DXA scans/patient after
stratification taking the first DXA as normal (5 (3) DXA/patient),
osteopenia (4 (3) DXA/patient), and osteoporosis (4 (2) DXA/
patient) (p = 0.111).
Table 1. Epidemiological and clinical data at first DXA scan.
Gender, male, n (%) 284 (73%)
Menopause, n (%) 10 (9.5%)
Age, years 39.4 (34.9; 44.2)
BMI, kg/m2 22.5 (20.9; 24.6)
Calcium intake, g/d 16 (4%)
Hepatitis B/C coinfection, n (%) 93 (29%)
Concomitant therapy, n (%)
Hormone treatment, n (%) 3 (1%)
Alendronate, n (%) 7 (2%)
Time since HIV diagnosis, years 7.9 (3.7; 12.1)
Current CD4+, absolute value, cells/mL 514 (348.5; 746.5)
Nadir CD4+, cells/mL 219.5 (106.8; 318.3)
Suppressed viral load, n (%) 268 (68.5%)
Proportion of time with
suppressed viral load, n (%)
30.6 (11.7; 49.3)
Naı¨ve, n (%) 48 (12%)
Time on antiretroviral therapy, years 4.8 (1.5; 8.5)
Current use of protease inhibitors, n (%) 171 (50%)
Time on protease inhibitors, years 2.4 (1.2; 4.1)
Current use of tenofovir, n (%) 173 (51%)
Time on tenofovir, years 1 (0.3; 2.3)
Creatinine, mmol/L 87 (76; 97.5)
Values are expressed as median (IQR) or number (%).
doi:10.1371/journal.pone.0046031.t001
Progression to Osteoporosis in HIV-Infection
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Figure 1. Time of progression. Time of progression from normal bone mineral density to osteopenia overall (n = 112 patients) (A) and after
stratification according to minimum baseline T score (‘‘low-risk’’, ‘‘middle-risk’’, and ‘‘high-risk’’) (B).
doi:10.1371/journal.pone.0046031.g001
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Median (IQR) time between DXA scans was 33.71 weeks (25.1;
56) (0.65 years); median (IQR) time between the first and the last
DXA scans was 133.1 weeks (62.7; 276.4) (2.6 years). No
differences were detected in median (IQR) time between the first
and the last DXA scans after stratification according to the first
DXA scan (data not shown).
Change from normal BMD at baseline to osteopenia
Median follow-up for the 112 patients from this group was 152
weeks (59.1; 258) (2.9 years). Forty of these 112 patients (35.7%)
progressed to osteopenia/osteoporosis.
The survival analysis showed a median (IQR) time of
progression to osteopenia of 349 weeks (74; 451) (6.7 years)
(Figure 1.A).
Patients with normal BMD at baseline were stratified in tertiles
according to the minimum T score of their first DXA, as follows:
‘‘low-risk’’ tertile when the minimum T score was .20.2 SD (38
patients, 33.9%), ‘‘middle-risk’’ tertile when the minimum T score
was between 20.2 and 20.6 SD (30 patients, 26.8%) and ‘‘high-
risk’’ tertile when the minimum T score was between 20.6 and
21 SD (44 patients, 39.3%) (Figure 1.B).
The three groups were similar with respect to age (p = 0.95),
gender (p = 0.72), time with infection (p= 0.064), percentage of
patients with viral suppression (p = 0.81), and CD4 T-cell count
(p = 0.359).
The survival analysis revealed significant differences in time of
progression after stratification by tertiles. Median (IQR) time of
progression overall was 451 weeks (349; 451) (8.7 years) in patients
from the ‘‘low-risk’’ tertile, .375 weeks (.375; .375) (.7.2
years) in those who were in the ‘‘middle-risk’’ tertile, and 88 weeks
(39; 190) (1.7 years) in those who were in the ‘‘high-risk’’ tertile
(p,0.0001) (Figure 1.B).
Table 2 shows those of the 112 patients whose status progressed
from normal to osteopenia/osteoporosis after stratification by
baseline minimum T score (‘‘low-risk’’, ‘‘middle-risk’’, and ‘‘high-
risk’’).
When patients were stratified by age tertiles in the same group,
differences in time of progression were observed when we applied
the following tertiles: those aged ,30 years (20 patients, 17.9%),
those aged 30–50 years (85 patients, 75.9%), and those aged .50
years (7 patients, 6.3%) (p=0.016), but not when we applied the
tertiles ,33, 33–39, and .39 years (p = 0.418) (Figure 2.A and
2.B).
When patients were stratified by both the minimum T score of
baseline DXA scan and by age, the median time of progression
was significantly shorter in tertiles with a T score ,20.4,
independently of age, than in those with a T score $20.4
(p=0.0003) (Figure 2.C).
No statistically significant differences were observed when
patients were classified according to gender: time of progression
was .392 weeks (130; .392) (.7.5 years) in women (n= 35) and
238 weeks (72; 451) (4.6 years) in men (n = 77) (p=0.136).
Change from osteopenia at baseline to osteoporosis
A total of 211 patients had osteopenia at baseline; of these, 194
presented osteopenia at their first DXA scan and the remaining 17
had a normal DXA result at baseline, progressed to osteopenia in
a subsequent DXA, and underwent additional DXA scans.
Median follow-up for the 211 patients from this group was 128
weeks (60.4; 279) (2.7 years). Fifty of these 211 patients (23.7%)
progressed to osteoporosis.
Survival analysis showed a median (IQR) time of progression to
osteoporosis of .443 weeks (186; .443) (.8.5 years) (Figure 3.A).
When the 211 patients were stratified according to the
minimum T score of the first DXA scan, 73 (34.6%) were classed
as ‘‘low-risk’’ (between 21.6 and 21.1 SD), 63 (29.9%) as
‘‘middle-risk’’ (between22 and21.6 SD and 75 (35.5%) as ‘‘high-
risk’’ (between 22.4 and 22 SD) (Figure 3).
The 3 groups were similar with respect to age (p=0.106),
gender (p=0.103), percentage of patients with viral suppression
(p = 0.602), and CD4 T-cell count (p=0.739), but not by time with
infection, which was higher in patients from the ‘‘high-risk’’ tertile
with respect to the ‘‘low-risk’’ tertile (9.4 years vs 7.8 years,
p=0.043).
The survival analysis showed significant differences in time of
progression to osteoporosis between the 3 groups, as follows:
median (IQR) time of progression of .425 weeks (359; .425),
(.8.2 years) in the ‘‘low-risk’’ tertile, .443 weeks (347; .443)
(.8.5 years) in the ‘‘middle-risk’’ tertile, and 164 weeks (53; 364)
(3.2 years) in the ‘‘high-risk’’ tertile (p,0.0001) (Figure 3.B)
Table 3 shows those of the 211 patients who progressed from
osteopenia to osteoporosis stratified by minimum T score (‘‘low-
risk’’, ‘‘middle-risk’’, and ‘‘high-risk’’).
When patients were stratified by age tertiles, no significant
differences were seen for ,37 years (74 patients, 35%), 37–43
years (74 patients, 35%), or .43 years of age (63 patients, 30%)
(p=0.214) (Figure 4.A).
When patients were stratified by both the minimum values of
the T score of the DXA scan and age, median time of progression
was significantly shorter in the group with a T score ,21.8 and
age .40 years (p,0.0001) (Figure 4.B).
No differences were seen when patients were classified
according to gender: median time of progression (IQR) was 359
(234; .443) weeks (6.9 years) in women (n= 60) and .428 weeks
(179; .428) (.8.2 years) in men (n= 151) (p=0.465).
As for patients with osteoporosis in the first DXA scan, 24.7%
improved (osteoporosis to osteopenia or normal BMD), while
75.3% remained unchanged.
Discussion
Among our chronically HIV-infected patients, nearly one-third
of those whose first DXA scan showed normal BMD progressed to
osteopenia. Median time of progression to osteopenia was almost 7
years, but in those patients with normal BMD but whose baseline
Table 2. Patients (n = 112) who progressed from normal bone
mineral density to osteopenia/osteoporosis.
Follow-up (weeks) HIGH-RISK MIDDLE-RISK LOW-RISK
48 25% 11% 3%
96 53% 19% 3%
144 70% 24% 20%
192 75% 24% 20%
240 84% 24% 20%
288 24% 20%
336 24% 20%
384 33%
432 33%
480 100%
doi:10.1371/journal.pone.0046031.t002
Progression to Osteoporosis in HIV-Infection
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minimum T score was in the ‘‘high-risk’’ tertile, this progression
was much faster (,2 years). Similarly, osteopenia progressed to
osteoporosis in a quarter of patients. Although time of progression
was more than 8 years, for patients with a minimum baseline T
score ,22 SD (lower tertile) it was 3 years.
Alterations in bone strength predispose to fragility fractures,
which are associated with increased morbidity and mortality in the
HIV-negative population. [1,24,25,30]
Prevention of osteoporotic fractures, then, is of major interest
from a public health perspective. In HIV-infected patients,
osteoporosis is probably underdiagnosed. Adequate tools should
be designed to identify patients at high risk for low BMD, who
would be candidates for BMD screening by DXA. In the last few
years, many efforts have been made to identify risk factors for bone
loss—other than traditional factors—among HIV-infected pa-
tients. [2,27,31] Age (.50 years), the menopause, other secondary
Figure 2. Survival analysis by age. Survival analysis in patients with normal bone mineral density at baseline stratified by age (,33 years, 33–38
years and.38 years [A] and,30 years, 30–50 years, and.50 years [B]) and by both age and T score (less or higher than20.4 and less or higher than
36 years [C]).
doi:10.1371/journal.pone.0046031.g002
Progression to Osteoporosis in HIV-Infection
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causes of low BMD, and a personal or family (parents) history of
fragility fractures, together with exposure to some antiretroviral
drugs (tenofovir and boosted protease inhibitors), are relevant risk
factors that speak in favor of screening with DXA. [31] The
optimal BMD testing intervals using DXA scans, however, has not
been established.
Data have been published on the rate of progression to bone loss
[32,33,34], although our results are the first to show the time of
progression to osteopenia/osteoporosis, information that is essen-
tial for monitoring. We observed that baseline T score, divided
into tertiles, enabled us to establish time of progression of bone loss
more accurately than the simple classification according to the
WHO criteria (normal, osteopenia, and osteoporosis). According
Figure 3. Time of progression to osteoporosis. Time of progression from osteopenia to osteoporosis overall (n = 211 patients) (A) and after
stratification by baseline minimum T score (‘‘low-risk’’, ‘‘middle-risk’’, and ‘‘high-risk’’) (B).
doi:10.1371/journal.pone.0046031.g003
Progression to Osteoporosis in HIV-Infection
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to our results, time of progression to osteopenia in patients with
normal BMD at the first DXA scan was enormously different
depending on the tertile in which the patient was classified at
baseline: from more than 8 years to less than 2 years according to
whether the T score was in the low-risk tertile (.20.2 SD) or if it
was in the lowest tertile (from 20.6 to 21 SD), respectively.
Similarly, the time of progression to osteoporosis varied widely
among patients with osteopenia in the first DXA scan according to
the tertile: 8 years for those whose minimum T score was in the
higher tertile (between 21.1 and 1.6 SD), but only 3 years for
those whose minimum T score was in the lowest tertile (from 22
to22.4 SD). Ourt results are consistent with recent published data
in older HIV-negative women. In this analysis of data from 4,957
women, baseline T score was the most determinant of a BMD
testing interval; osteoporosis developed in 15 years for women with
normal BMD or mild osteopenia (T score, greater than 21.5), 5
years for women with moderate osteopenia (T score from 21.5 to
21.99) and 1 year for women with advanced osteopenia (T score
from 22.0 to 22.49) [35].
Current recommendations on the study of bone disease for HIV
care providers mainly include information on candidates for BMD
monitoring by DXA, [22,29] but provide very little information on
the optimal frequency of subsequent DXA scans, based on the
WHO categories of BMD. [31] According to our data, a
reasonable proposal would be to set the frequency of DXA
according to the tertile: patients in the lowest T score tertiles
(defined as a T score from 20.6 to 21 in patients with normal
BMD according to the WHO criteria, and from 22 to 22.4
among those with osteopenia) should undergo another DXA scan
more frequently than those in the other 2 tertiles. A subsequent
DXA scan should be recommended as soon as 1–2 years later for
those in the lower tertiles, even when baseline BMD had been
classified as normal; this frequency will help to diagnose early
changes in BMD status (from normal BMD to osteopenia or from
osteopenia to osteoporosis) and, in the case of progression, enable
appropriate measures to be taken. Patients in the other 2 tertiles (T
score from 20.6 to .20.2 in patients with normal BMD and
from 21.1 to 22 among those with osteopenia) could be assessed
by a DXA scan after at least 6–7 years, even in those whose
baseline BMD fulfilled the criteria for osteopenia. Since it is
unlikely that a patient would progress in less than 7–8 years, more
frequent DXA scanning would not affect management, although it
would increase costs and inconvenience to patients.
Given our results, similar recommendations on the frequency of
DXA scan should be implemented according to age, providing
that the decision is based on the T score. Although age affected
bone loss, when patients were classified according to their initial T
score (tertiles), BMD status gave more information on the
progression of bone loss. In clinical terms, however, the negative
effect of age on risk of osteoporotic fracture, independently of
BMD, has been reported, suggesting that both age and BMD
should be taken into consideration [36] The lack of elderly patients
prevents us from assessing this issue in greater depth.
As for gender, although no statistically significant differences
were detected between men and women, variations in the time of
progression to osteopenia/osteoporosis could be clinically relevant:
those men with a normal baseline BMD, included in the high-risk
tertile, progressed more rapidly to osteopenia than women
(median of progression of 4.6 years in men and .7.5 years in
women). This finding could suggest the need for special care and
more rigorous monitoring of men from this group. These data are
consistent with other published results showing the higher
prevalence of low BMD and fragility fractures in men than in
premenopausal women. [25]
As a retrospective observational study, our analysis presents
some limitations. Variables were recorded using clinical docu-
ments as the source. Consequently, the first DXA scan for each
patient did not correspond to a defined baseline; however, since at
that time DXA scan was only performed when patients were seen
for first time in our unit or in the context of clinical assays
(metabolic studies, new antiretroviral strategies, antiretroviral-
naive patients…), subjects included in the analysis seem to be a
good representation of our population. Additionally, the time from
normal BMD to osteopenia is only known to lie within the time
interval between the first DXA with a value,21 SD and the time
immediately before this scan; the time from osteopenia to
osteoporosis is only known to lie within the time interval between
the first DXA with a value ,22.5 SD and the time immediately
before this scan. Our analysis imputed the right end of this
interval, that is the time with the first DXA,21 SD as the time to
osteopenia and ,22.5 SD as the time to osteoporosis. A statistical
analysis taking into account the random nature of the intervals,
where the change of status occurs, could diminish the bias due to
this finding. [37] However, it is our belief that the effect of these
limitations on the conclusions would be negligible. Finally, the
retrospective nature of the analysis avoids knowing the presence of
some clinical factors that may contribute to a different bone loss
progression or bone recovery (steroid use, menopause, hypogo-
nadism, bisphosphonate use, vitamin D or calcium supplementa-
tion, etc).
To conclude, in HIV-infected patients, the use of screening
thresholds based on the minimum T scores (tertiles) provided by
DXA is more efficient for predicting time of progression to
osteopenia/osteoporosis and deciding on BMD testing intervals
than the WHO criteria. The lowest minimum T-score tertiles
indicate the recommendation of a subsequent DXA scan in 1–2
years, while in the highest tertiles, this interval could be 6 years or
more. Since management algorithms are lacking, ours and other
data are necessary to facilitate the design of suitable guidelines for
this population. Early intervention in patients with bone demin-
eralization could reduce the high morbidity and mortality
associated with osteoporotic fractures.
Table 3. Patients (n = 211) who progressed from osteopenia
to osteoporosis (B) after stratification according to minimum T
score (‘‘low-risk’’, ‘‘middle-risk’’ and ‘‘high-risk’’).
Follow-up (weeks) HIGH-RISK MIDDLE-RISK LOW-RISK
48 22% 2% 0%
96 40% 9% 0%
144 60% 9% 0%
192 71% 13% 4%
240 71% 20% 9%
288 71% 24% 9%
336 71% 24% 18%
384 36% 28%
432 36%
480
doi:10.1371/journal.pone.0046031.t003
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